Alpha-GPC vs Exenatide
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Alpha-GPC is the most bioavailable form of choline, readily crossing the blood-brain barrier to rapidly increase acetylcholine levels. It enhances cognitive performance, supports GH secretion, and is used as an essential complement to many nootropic peptides (especially those that increase acetylcholine demand like Noopept and Dihexa).
- Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
- Half-Life
- ~4–6 hours
- ~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
- Admin Route
- Oral, SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 300–600 mg
- 5 mcg, titrate to 10 mcg
- Frequency
- 1–2x daily
- Twice daily
- Key Benefits
- Rapidly raises brain acetylcholine levels
- Enhances memory formation and recall
- Prevents headaches from nootropic peptides (choline donor)
- Stimulates growth hormone secretion (modest)
- Improves attention and processing speed
- Neuroprotective in Alzheimer's and cognitive decline
- Approved in Europe for Alzheimer's therapy
- Enhances power output in athletes (pre-workout)
- Blood glucose control in type 2 diabetes
- Weight loss (average 2–3 kg in clinical trials)
- Once-weekly extended-release formulation available
- Reduces appetite and food intake
- Possible neuroprotective in Parkinson's disease (Phase II trials)
- Reduces systemic inflammation
- May protect pancreatic beta cells
- Cardiovascular neutral or potentially protective
- Side Effects
- Headache (paradoxically, from excess acetylcholine at very high doses)
- Nausea at doses > 1200 mg
- Dizziness
- Fatigue at high doses
- +1 more
- Nausea (most common, especially initially)
- Vomiting
- Diarrhea
- Headache
- +4 more
- Stacks With
- —
- —